Evaluation of a novel 177 Lu-labelled therapeutic Affibody molecule with a deimmunized ABD domain and improved biodistribution profile.
Yongsheng LiuMaryam OroujeniYunqi LiaoAnzhelika VorobyevaVitalina BodenkoAnna OrlovaMark KonijnenbergMatilda CarlqvistElisabet WahlbergAnnika LofteniusFredrik Y FrejdVladimir TolmachevPublished in: European journal of nuclear medicine and molecular imaging (2024)
Lu]Lu-PEP49989 demonstrated favourable biodistribution and a strong antitumour effect, which was further enhanced by co-treatment with trastuzumab.